GSK plans phase 3 for hepatitis B drug bepirovirsen, despite efficacy drop

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable levels of the virus compared to an earlier readout.